NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, News, & Analysis

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals announced that its Board of Directors has authorized a stock repurchase program on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 3.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company's leadership believes its shares are undervalued.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its earnings results on Thursday, July, 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $1.49 by $0.58. The biopharmaceutical company earned $1.05 billion during the quarter, compared to the consensus estimate of $976.81 million. Alexion Pharmaceuticals had a positive return on equity of 15.21% and a negative net margin of 2.68%. The firm's revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.56 EPS. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals updated its FY18 earnings guidance on Thursday, July, 26th. The company provided earnings per share guidance of $7.00-7.15 for the period, compared to the Thomson Reuters consensus estimate of $7.02. The company issued revenue guidance of $3.98-4.01 billion, compared to the consensus revenue estimate of $4.00 billion.

18 analysts have issued twelve-month target prices for Alexion Pharmaceuticals' stock. Their predictions range from $123.00 to $188.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $159.00 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 2 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

Some companies that are related to Alexion Pharmaceuticals include Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY) and Teva Pharmaceutical Industries (TEVA).

Media headlines about ALXN stock have trended positive this week, Accern reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a media and rumor sentiment score of 0.28 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 48.98 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Alexion Pharmaceuticals.

Alexion Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (8.76%), BlackRock Inc. (7.30%), Jennison Associates LLC (2.70%), Bank of New York Mellon Corp (1.36%), Iridian Asset Management LLC CT (0.67%) and Wells Fargo & Company MN (0.67%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, Edward Miller, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Leonard Bell, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Jennison Associates LLC, Millennium Management LLC, Waddell & Reed Financial Inc., Morgan Stanley, Janus Henderson Group PLC, Connor Clark & Lunn Investment Management Ltd. and Virginia Retirement Systems ET AL. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Ann M Veneman, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was acquired by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Advisors Asset Management Inc., Sound Shore Management Inc. CT, Swedbank, Putnam Investments LLC, Point72 Asset Management L.P., Bessemer Group Inc. and Nomura Holdings Inc.. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $116.00.

Alexion Pharmaceuticals has a market capitalization of $26.49 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]